This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Small Molecule Drugs
Skimune® can predict first-in-man hypersensitivity or adverse immune reactions to small molecule therapeutics.
Benefits of the Skimune® assay
Detection of clinically relevant celluar immune responses
Validated against commercially available therapeutic small monoclonal drugs
Available in combination with complementary assays
Non-animal system
For more information on Skimune® assays and how they can help your business R&D please contact us.
Get in touchCase Study:
In collaboration with Pfizer (1) we validated our Skimune® explant assays against a range of small molecule drugs and compared results to T-cell proliferation cytokine release. The skin explant assay offers a human in vitro model with a novel endpoint to predict the potential of a drug to cause drug hypersensitivity reactions (DHRs) which standard toxicology tests do not offer. The skin damage observed in response to drug exposure is reflective of immune activation and the production of cytokine and other cytotoxic molecules by the activated T-cells.
The study outcome demonstrates that the skin explant assay could be used as a valuable predictive pre-clinical tool either as an independent test or in conjunction with in vivo assays.
The study outcome demonstrates that the skin explant assay could be used as a valuable predictive pre-clinical tool either as an independent test or in conjunction with in vivo assays.
(1) Toxicol Appl Phamacol. 2019: 369, 39-48. doi: 10.1016/j.taap.2019.02.005 Ahmed SS, Whritenour J, Ahmed MM, BibbyL, Darby L, Wang XN, Watson J, Dickinson AM.
